ArticleBMJ oncology2025

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.

Helena M Earl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.